{"id":"W2921633401","doi":"10.1200/jco.2019.37.7_suppl.543","title":"Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for locally advanced or metastatic renal cell carcinoma (mRCC): phase III KEYNOTE-426 study.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université de Montréal; Université Laval","funders":"","keywords":"Medicine; Sunitinib; Renal cell carcinoma; Clinical endpoint; Temsirolimus; Internal medicine; Interim analysis; Oncology; Tolerability; Discontinuation; Phases of clinical research; Adverse effect; Clinical trial; Discovery and development of mTOR inhibitors","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002984673,0.002276933,0.002662167,0.0005153836,0.0005377036,0.001257335,0.001684471,0.001758325,0.008660186],"category_scores_gemma":[0.001448222,0.0009436044,0.001717988,0.0005732581,0.0009998436,0.00119633,0.0005615068,0.004013652,0.001930459],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001328008,"about_ca_system_score_gemma":0.002371207,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001209961,"about_ca_topic_score_gemma":0.003236652,"domain_scores_codex":[0.9994252,0.0002911605,0.00002785272,0.00009845244,0.00005532608,0.000102055],"domain_scores_gemma":[0.9990355,0.000156624,0.0001955419,0.00006479864,0.00005069314,0.0004968021],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9270141,0.03243868,0.001067297,0.001123513,0.001294554,0.00008430237,0.0001119215,0.0009064961,0.009421944,0.0001339034,0.002313773,0.02408958],"study_design_scores_gemma":[0.8238716,0.1688396,0.003350648,0.00004763902,0.0006497689,0.0001190806,0.00002943471,0.0005134273,0.00100217,0.0001357616,0.001423293,0.00001746345],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9725317,0.005457978,0.00131528,0.0009616224,0.0003764874,0.01047916,0.004109926,0.0002511086,0.00451679],"genre_scores_gemma":[0.9758955,0.003892555,0.002419337,0.001739258,0.0003506874,0.006703029,0.00352056,0.00005895145,0.005420206],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008660186,"threshold_uncertainty_score":0.02897125,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1810780836813065,"score_gpt":0.4758328862607582,"score_spread":0.2947548025794516,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}